BRAIN
NCCTG N0779 Consent
HIPAA
Protocol
Phase II Study of Vorinostat (SAHA) in
combination with Bortezomib (PS-341) in Patients
with Recurrent Glioblatoma Multiforme
NCCTG N0272A(phase 1)
Consent
HIPAA
Protocol
(temporary closure Arm C-EIAC's patients) NCCTG N0272B(phase 2)
Consent
A Phase I/II Trial of Imatinib
Mesylate (Gleevec) in Treatment of Recurrent Oligodendroglioma and Mixed
Oligoastrocytoma
RTOG R0625 Consent
HIPAA
Protocol
Application
Information (Temporary
closure)
A Randomized
Phase II Trial of Bevacizumab with Irinotecan or
Bevacizumab with Temozolomide in Recurrent
Glioblastoma
Central
Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent
Disease, Ancillary
Brain Mets
NCCTG N0574
Consent
HIPAA
Protocol
Phase III
Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to
Radiosurgery in Patients with One to Three Cerebral Metastases
BREAST
Breast DCIS
Breast - Node
Positive
Breast - Node
Negative
CTSU PACCT-1 TAILORx
Consent HIPAA
Fast Facts
Protocol
Patient Information
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial
Assigning Individualized Options for Treatment: The TAILORx Trial
NSABP
B-36
Consent
HIPAA
Fast Facts
Protocol
A Clinical Trial of Adjuvant Therapy Comparing Six
Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide to Four Cycles of Adriamycin and
Cyclophosphamide, With or Without Celecoxib, in patients with Node-Negative Breast Cancer
Breast -
Node Positive or Negative
CTSU
N063D ALTTO
Consent
HIPAA
Fast Facts
Protocol
A
Randomized, Multi-center, Open-label, Phase III
Study of Adjuvant Lapatinib, Trastuzumab, Their
Sequence and Their Combination in Patients with
HER2/ErbB2 Positive Primary Breast Cancer
SWOG S0221
Consent HIPAA
Protocol Fast
Facts
Antioxidant Use
Phase III Trial of Continuous Schedule AC + G
vs. Q-2
Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks
as Postoperative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast
Cancer
SWOG
S0307
Consent
HIPAA Fast
Facts
Protocol
Phase III
Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast
Cancer
CTSU CALGB 40101
Consent
HIPAA
Fast Facts
Protocol
Cyclophosphamide and Doxorubicin vs. Paclitaxel as
Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph
Nodes
CTSU CALGB
70301 Consent
HIPAA
Schema
Protocol
Quality of Life, Employment, and Informal Care Cost Analysis in Women Receiving
Adjuvant Chemotherapy (Adjunct study for C40101)
CTSU E5103
Consent
HIPAA
Fast
Facts Protocol
A Double-blind Phase III Trial
of Doxorubicin and Cyclophosphamide followed by
Paclitaxel and Bevacizumab or Placebo in
Patients with Lymph Node Positive and High-risk
Lymph Node Negative Breast Cancer
CTSU N0434 (MA.27D)
Consent HIPAA
Fast Facts
Protocol
Association
of Breast Density Changes, Plasma Hormone Changes and Breast Cancer Recurrence
(Companion MA.27D)
NSABP B-39
Consent
HIPAA
Fast Facts
Protocol
(Closed to specific patients)
A Randomized Phase III Study of Conventional
Whole Breast Irradiation versus Partial Breast Irradiation for Women with Stage
0, I or II Breast Cancer
NSABP B-40
Consent
HIPAA
Fast Facts
Protocol
A
Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and
Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR)
of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC
with or without Bevacizumab and Correlative Science Studies Attempting to
Identify Predictors of High Likelihood for pCR with Each of the Regimens
NSABP B-41
Consent
HIPAA
Fast Facts
Protocol
(Hold for regulatory)
(Temporary closure 6/11/08)
A
Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and
Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab
Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly
Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify
Predictors of Pathologic Complete Response
NSABP B-42
Consent
Consent #2-Reg.
HIPPA HIPPA-Reg.
Protocol
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal
Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI
in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Ovarian Function Failure
SWOG S0230
Consent
HIPAA Fast
Facts
Protocol
Phase III Trial of LHRH Analog Administration During
Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early
Stage, Hormone-Receptor Negative Breast Cancer
Breast - Inflammatory
Breast - Relapse
NSABP B-37
Consent
HIPAA
Fast Facts Protocol
A Randomized Clinical Trial of Adjuvant
Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer
Breast - Metastatic
SWOG S0226
Consent HIPAA
Fast Facts
Protocol
Phase III Randomized Trial of Anastrozole vs. Anastrozole
and Fulvestrant as First-Line Therapy for Post Menopausal Women with Metastatic Breast
Cancer
SWOG S0500
Consent
HIPAA
Fast Facts
Protocol
A Randomized Phase
II Trial to Test the Strategy of Changing Therapy vs Maintaining Therapy for
Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell
Levels at First Follow-up Assessment
SWOG S0622
Consent HIPAA
Fast Facts
Protocol
Phase II Studies of
Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant
Metastatic Breast Cancer
CTSU CALGB 40302
Consent
HIPAA Fast
Facts
Protocol
Investigator
letter
Endocrine
Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors:
A Randomized, Double-Blinded, Placebo-controlled Phase III Trial of Fulvestrant
with or without Lapatinib for Postmenopausal Women with Hormone Receptor
Positive Advanced Breast Cancer
CTSU E1105 Consent
HIPAA
Fast Facts
Protocol
A
Randomized Phase III Double-Blind
Placebo-Controlled Trial of First-line
Chemotherapy and Trastuzumab with or without
Bevacizumab for Patients with HER-2/NEU
Over-expressing Metastatic Breast Cancer
NCCTG
N0539
Consent
HIPAA
Protocol (Study requires N0392 adjunct study)
Phase II Trial of Fulvestrant and
Bevacizumab in Patients with Metastatic Breast
Cancer Previously Treated with an Aromatase
Inhibitor
Breast-Other
SWOG JMA.17R
Consent
HIPAA Protocol
A Double Blind Randomization To Letrozole or Placebo For
Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of
Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen
(including those in the MA.17 study)
NSABP BP-59
Consent
HIPAA
Fast Facts
Protocol
Bone Marrow Analysis in
Early-Stage Breast Cancer
IBCSG 24-02 Consent
HIPAA Fast Facts
Protocol
A Phase III Trial Evaluating the Role of Ovarian
Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women
with Endocrine Responsive Breast Cancer
NCCTG N063I
Consent
HIPAA
Protocol
Changes in Breast Density and Plasma Hormone
Levels After One Year of Aromatase Inhibitor
Therapy
GASTROINTESTINAL
Colon - Rectal
NSABP LTS-01
Consent
HIPAA
Protocol
Patient Reported Outcomes in Long-term Survivors
with Colon and Rectal Cancer
SWOG S0600
Consent
HIPAA Fast
Facts
Protocol
(temporary closure 6/9/08)
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without
Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal
Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
CTSU E5202
Consent
HIPAA
Protocol
A
Randomized Phase II Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU,
Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer
at High Risk for Recurrence to Determine Prospectively the Prognostic Value of
Molecular Markers
CTSU N0147
Consent HIPAA
Fast Facts
Protocol
(temporary closure 6/9/08)
A Randomized Phase III
Trial of Irinotecan and/or Oxaliplatin Plus 5-Fluorouracil/Leucovorin with or
without Cetuximab (C225) after Curative
Resection for Patients with Stage III Colon Cancer
NSABP
C-10
Consent
HIPAA
Fast Facts
Protocol
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)
Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon
Cancer and a Synchronous Asymptomatic Primary Tumor
CTSU CALGB 80405
Consent
HIPAA
Fast Facts
Protocol
(Closure QOL) (temporary closure 6/9/08)
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin
with Bevacizumab, or Cetuximab or with the Combination of Bevacizumab and
Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or
Rectum
NCCTG
N0543
Consent
HIPAA
Protocol
A Phase II Trial of
Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as
First-Line Therapy for Advanced Small Bowel Adencarcinoma
Rectal
NSABP R-04
Consent
Consent tissue
HIPAA
Fast Facts
Protocol
A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion of
5-Fluorouracil in the Treatment of Patients with Operable Carcinoma of the Rectum
CTSU E5204
Consent
HIPAA
Fast Facts
Protocol
Intergroup
Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and
Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for
Patients with Stage II or III Rectal Cancer Receiving Preoperative
Chemoradiation
Stomach
CTSU
C80101
Consent
HIPAA
Fast Facts
Protocol
A Phase III
Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or
Gastroesophageal Adenocarcinoma
Esophageal
RTOG R0436
Consent
HIPAA
Protocol
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and
Radiation for Patients With Esophageal Cancer
Who Are Treated Without Surgery
Pancreas
None
Gallbladder
None
Other
SWOG S0502
Consent
HIPAA
Protocol
A Phase III
Randomized Trial of Imatinib, with or without
Bevacizumab in Patients with Metastatic or
Unresectable Gastrointestinal Stromal Tumors
GENITOURINARY
Prostate
SWOG 9346
Consent
HIPAA
Protocol
(closure 9/1/2008)
Intermittent Androgen Deprivation in Patients with Stage
D2 Prostate Cancer
SWOG S0421
Consent
HIPAA
Protocol
Phase III Study of
Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced
Hormone Refractory Prostate Cancer
CTSU E3805
Consent
HIPPA
Protocol
CHAARTED:
Chemohormonal Therapy versus Androgen
Ablation Randomized Trial for Extensive
Disease in Prostate Cancer
CTSU CALGB 90202
Consent
HIPAA
Fast Facts
Protocol
A Randomized, Double-blind, Placebo-controlled Phase III
Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal-related Events in Men with
Prostate Cancer Metastatic to Bone
CTSU CALGB 90203
Consent
HIPAA
Protocol
Randomized Phase III Study of
Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs
Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized
Prostate Cancer
CTSU MDA-3410
Consent
HIPAA
Fast Facts
Protocol
A Prospective Randomized Phase II Trial Comparing
Consolidation Therapy With or Without Strontium-89 Following Induction
Chemotherapy in Androgen-Independent Prostate Cancer
CTSU RTOG 0521
Consent Consent
for Tissue
HIPAA
Protocol
A Phase III Protocol of
Androgen Suppression (AS) and Radiotherapy (RT) vs AS and RT Followed by
Chemotherapy with Doxetaxel and Prednisone for Localized High-Risk Prostate
Cancer
CTSU RTOG 0415
Consent
HIPAA
Fast Facts
Protocol
Pre-registration requirements (see section 5.0
of the protocol)
A Phase III Randomized Study of Hypofractinated 3D-CRT/IMRT Versus
Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate
Cancer
RTOG R0534
Consent
HIPAA
Protocol
A Phase III Trial
Of Short Term Androgen Deprivation With Pelvic
Lymph Node Or Prostate Bed Only Radiotherapy
(SPORT) In Prostate Cancer Patients With A
Rising PSA After Radical Prostatectomy
Bladder/Urothelium
SWOG S0337 Consent
HIPAA
Protocol
A Phase III
Blinded Study of Immediate Post-TURBT
Instillation of Gemcitabine Versus Saline in
Patients with Newly Diagnosed or Occasionally
Recurring Grade I/II Superficial Bladder Cancer
SWOG S0353
Consent
HIPAA
Fast Facts
Protocol
Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder
Cancer Who Have Progressed Despite Intravesical BCG
Germ Cell Malignancies
none
Renal
CTSU
E2805
Consent
HIPAA
Fast Facts
Protocol
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus
Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
CTSU
E2804 Consent
HIPAA
Protocol
The BeST Trial: A
Randomized Phase II Study of VEGF, RAF kinase,
and mTOR Combination Targeted Therapy (CTT) with
Bevacizumab, Sorafenib and Temsirolimus in
Advanced Renal Cell Carcinoma
GYNECOLOGIC
Ovarian
CTSU GOG
0218 Consent
HIPAA
Fast
Facts Protocol
A Phase III Trial of Carboplatin and Paclitaxil plus Placebo versus Carboplatin
and Paclitaxil plus Concurrent Bevacizumab followed by Placebo versus
Carboplatin and Paclitaxil plus Concurrent and Extended Bevacizumab in Women
with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial
Ovarian and Primary Peritoneal Cancer
Cervical
CTSU GOG 0219
Consent
HIPAA
Fast Facts
Protocol
A Phase III Randomized Trial of Weekly
Cisplatin and Radiotherapy versus Cisplatin and Tirapazamine and Radiotherapy in
Stage IB2, IIA, IIIB, and IVA Cervical Cancer Limited to the Pelvis
Endometrial
CTSU GOG 0209
Consent
HIPAA
Fast Facts
Protocol
(Temporarily closed to patients who have received any prior external RT)
Randomized Phase III Trial of
Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with
Stage III & IV or Recurrent Endometrial Cancer
HEAD & NECK
CTSU E1302
Consent
HIPAA
Fast Facts
Protocol
(Arm
C partial
closure)
Phase III Randomized,
Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839(Iressa,
Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent
or Metastatic Head and Neck Cancer
RTOG
R0435
Consent
HIPAA
Protocol
Training
Pre-registration requirements (see section 5.0
of the protocol)
Randomized, Phase III,
Double-Blind,
Placebo-Controlled Study to Evaluate the
Efficacy and Safety of Palifermin (NSC#740548m
IND 6370) for the Reduction of Oral Mucositis in
Patients with Locally-Advanced Head and Neck Cancer Receiving Radiation Therapy
with concurrent Chemotherapy (Followed by surgery for Selected Patients)
CTSU RTOG 0522
Consent HIPAA
Fast
Facts
Protocol
PET Requirements and
Credentialing
A Phase III Trial of
Concurrent Accelerated Radiation and Chemotherapy vs Concurrent Accelerated
Radiation, Chemotherapy and Cetuximab (C225) for Stage III and IV Head and Neck
Carcinoma
LEUKEMIA
Acute Leukemia
SWOG 9007
Consent
HIPAA
Protocol
Cytogenetics Studies in Leukemia Patients, Ancillary
SWOG 9910
Consent
HIPAA
Protocol
Leukemia Centralized Reference Laboratories and Tissue
Repositories Consent to Perform Cellular and Molecular Studies in Leukemia Patients
SWOG S0106
Consent HIPAA
Protocol
A Phase III Study of the Addition of Gemtuzumab
Ozogamicin During Induction Therapy vs. Standard Induction with Daunomycin and Cytosine
Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation
Therapy with Gemruzumab Ozogamicin or No Additional Therapy for Patients Under Age 56 with
Previously Untreated De Novo Acute Myeloid Leukemia
SWOG S0535
Consent
HIPAA
Protocol
Phase II Study of ATRA, Arsenic
Trioxide and Gemtuzumab Ozogamicin in Patients
with Previously-untreated High-risk Acute
Promyelocytic Leukemia
SWOG S0605
Consent
HIPAA
Protocol
A Phase II Study of Lenalidomide (Revlimid)
(NSC-703813) for Previously Untreated Non-M3 Deletion 5Q Acute Myeloid Leukemia
(AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
SWOG S0521
Consent
HIPAA
Protocol
A Randomized Trial of Maintenance
vs Observation for Patients with Previouslly Untreated Low and Intermediate risk
Acute Promyelocytic Leukemia (APL), Phase III
CTSU
E2902
Consent
HIPAA
Fast Facts
Protocol
A Phase III Randomized Study of Farnesyl
Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second
or Subsequent Remission or in Remission after Primary Induction Failure
CTSU E1900
Consent
HIPAA
Protocol
(Arm D Suspended) (temporary closure 2/16/08)
A Phase III Trial in Adult
Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and
Gentuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell
Transplantation Study
SWOG E1905
Consent
HIPAA
Protocol
(Temporary Closure)
A
Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase
Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic
Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with
Multilineage Dysplasia
Chronic Leukemia
SWOG S0325
Consent
HIPAA
Protocol
(Arm II only closed to accrual)
A Phase IIb Study of Molecular Responses to
Imatinib at Standard or Increased Doses for Previously Untreated Patients with
Chronic Myelogenous Leukemia (CML) in Chronic Phase
NCCTG N0683 Consent
HIPAA
Protocol
A Phase II Study of Sunitinib
Malate for Treatment of Patients with
Relapsed/Refractory Chronic Lymphocytic Leukemia
(CLL) or Small Lymphocytic Lymphoma (SLL)
SWOG E1905
Consent
HIPAA
Protocol
(Temporary closure)
A
Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase
Inhibitor MS-275 for the Treatment of Myeolodysplastic Syndrome, Chronic
Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with
Multilineage Dysplasia
Lymphoblastic Leukemia
SWOG S0333
Consent
HIPAA
Protocol
A Phase II
Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute
Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk
of Relapse Following Maintenance Chemotherapy
SWOG C10403 Consent
HIPAA
Protocol
(MCC treats adults only -- must be
> 18 yrs)
An Intergroup Phase II Clinical Trial for
Adolescents and Young Adults with Untreated
Acute Lymphoblastic Leukemia
CTSU
C10501 Consent
HIPAA
Fast Facts
Protocol
A
Phase III Intergroup CLL Study of Asymptomatic
Patients with Untreated CLL Randomized to Early
Intervention vs Observation with Later Treatment
in Hi-Risk Genetic Subset with IgVh Unmutated
Disease
LUNG
SWOG 9925
Protocol (NO CONSENT)
Lung Cancer Specimen Repository Protocol,
Ancillary
Non-Small Cell
SWOG 0229
Consent
HIPAA
Protocol
A Randomized Trial Assessing the Effects of
Exercise on Patients with Locally-Advanced Non-Small Cell Lung Cancer Undergoing
Curative-Intent Combined Modality Therapy (Ancillary to S0023)
SWOG
S0424
Consent
HIPAA
Fast Facts
Protocol
(study open only
to non-smokers - fewer than 100 cigarettes in lifetime)
Molecular
Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and
Non-Smoking Women and Men
SWOG
S0429
Consent
HIPAA
Fast Facts
Protocol
A Pilot
(Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor
Risk Stage III Non-Small Cell Lung Cancer
SWOG S0526 Consent
HIPAA
Fast Facts
Protocol
(permanent closure 10/1/08)
Phase II Trial of Pemetrexed in Patients
with Selected Stage IIIB and IV Bronchioalveolar
Carcinoma (BAC)
SWOG S0636
Consent
HIPAA Fast Facts
Protocol
A
Phase II Trial of the Combination of OSI-774 (Erlotinib;
NSC-718781) and Bevacizumab (Rhumab VEGF;
NSC-704865) in Never-Smokers with Stage IIIB and
IV Primary NSCLC Adenocarcinomas
SWOG E5597
Consent
HIPAA
Protocol
Phase III Chemoprevention Trial of Selenium
Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
NCCTG N0528
Consent
HIPAA
Protocol
A
Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171
as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCCTG
N0626
Consent
HIPAA
Protocol
A Phase II Randomized
Study of Pemetrexed With Sorafenib Versus
Pemetrexed Alone as Second-line Therapy in
Patients With Advanced Non-Small Cell Lung
Cancer
RTOG R0617
Consent
HIPAA
Protocol
A
Randomized Phase III Comparison of
Standard-Dose (60 Gy) Versus High-Dose (74
Gy) Conformal Radiotherapy with Concurrent
and Consolidation Carboplatin/Paclitaxel in
Patients With Stage IIIA/IIIB Non-Small Cell
Lung Cancer
CTSU E1505
Consent
HIPAA
Fast Facts
Protocol
A Phase III
Randomized Trial of Adjuvant Chemotherapy with
or without Bevacizumab for Patients with
Completely Resected Stage IB (> 4 cm) -
IIIA Non-Small Cell Lung Cancer
Small
Cell
CTSU
C30610 Consent
HIPAA
Protocol
Phase III Comparison of Thoracic Radiotherapy
Regimens in Patients with Limited Small Cell
Lung Cancer also Receiving Cisplatin and
Etoposide
RTOG R0623 Consent
HIPAA
Protocol
A Phase II Trial of Combined Modality
Therapy with Growth Factor Support for Patients
with Limited Stage Small Cell Lung Cancer
Lung-Other
NCCTG N0623 Consent
HIPAA
Protocol
Phase II Study of GW786034 in Patients with
Malignant Pleural Mesothelioma
SWOG S0635
Consent
HIPAA
Fast Facts
Protocol
Phase II
Trial of the Combination of OSI-774(Erlotinib)
and Bevacizumab in Stage IIIB
and IV Bronchoalveolar Carcinoma (BAC) and Adencarcinoma
with BAC Features (AdenoBAC)
LYMPHOMA
SWOG 8819
(NO CONSENT)
Protocol
Central Lymphoma Repository Tissue Procurement
SWOG 8947
Consent HIPAA
Protocol
Central Lymphoma Serum Repository
SWOG 9245 Consent
HIPAA
Protocol
Central Lymphoma Repository Tissue Procurement Protocol
for Relapse or Recurrent Disease
Hodgkin's
Non-Hodgkin's
SWOG
S0016
Consent
HIPAA
Fast Facts
Protocol
(Closing 9/15/2008)
A Phase III
Trial of CHOP vs. CHOP + Rituximab vs. CHOP + Iodine 131 Labeled Monoclonal Anti-B1
Antibody (Tositumomab) for Treatment of Newly
Diagnosed Follicular Non-Hodgkin’s
Lymphoma (Closure Arm 1)
SWOG S0350
Consent
HIPAA
Fast Facts
Protocol
Phase II
Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol in Peripheral
T-cell Non-Hodgkin's Lymphoma
SWOG S0433
Consent
HIPAA
Fast Facts
Protocol
Iodine-131-Labeled Monoclonal Anti-B1 Antibody in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy
for Patients Greater Than or Equal to Age 60 with Advanced Stage Diffuse Large
B-Cell NHL
SWOG S0515
Consent
HIPAA
Fast Facts
Protocol
(closing 9/15/2008)
Phase II Trial of Standard
Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab
Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL
SWOG S0520
Consent HIPAA
Fast Facts
Protocol
Phase II Study of PXD101 in
Relapsed and Refractory Aggressive B-Cell Lymphomas
CTSU E 4402 Consent
HIPAA
Fast
Facts
Protocol
(closing 9/12/2008)
A Randomized Phase III Trial Comparing Two Different
Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's
Lymphoma
CTSU CALGB 50303
Consent
HIPAA
Fast Facts
Protocol
Randomized Study of R-CHOP
versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated DeNovo
Diffuse Large B-Cell Lymphomas
NCCTG N0682
Consent
HIPAA
Protocol
A Phase II Clinical
Trial of Denileukin Diftitox in Combination with Rituximab in Previously
Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
NCCTG N0683 Consent
HIPAA
Protocol
A Phase II Study of Sunitinib
Malate for Treatment of Patients with
Relapsed/Refractory Chronic Lymphocytic Leukemia
(CLL) or Small Lymphocytic Lymphoma (SLL)
Mantle
Cell
NCCTG N038H
Consent
HIPAA
Protocol
(temporary closure 9/4/08))
A Phase II Study of CCI-779 in Combination
with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Melanoma
SWOG S0438 Consent
HIPAA
Protocol (temporary
closure 9/4/08)
A
Randomized Phase II Trial of BAY 43-9006 (Sorafenib)
with Either CCI-779 (Temsirolimus) or R115777
(Tipifarnib) in Metastatic Melanoma
SWOG
S0512
Consent
HIPAA
Protocol
(temporary closure effective
3/1/08)
Phase II
Trial of BAY 43-9006(Sorafenib) in Combination with Carboplatin and Paclitaxel
in Patients with Metastatic Uveal Melanoma
NCCTG
N0675 Consent
HIPAA
Protocol
A
Phase II Study of Temozolomide and Everolimus
(RAD-001) Therapy for Metastatic Melanoma
Myeloma
CTSU C100104
Consent
HIPAA
Protocol
A
Phase III Randomized, Double-blind Study of Maintenance Therapy with CC-5013 or
Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
CTSU E1A05
Consent
HIPAA
Protocol
Schema
Fast Facts
Randomized Phase III Trial of Consolidation
Therapy with Bortezomib (VelcadeŽ) -
Lenalidomide (RevlimidŽ) - Dexamethasone (VRD)
versus Bortezomib (VelcadeŽ) - Dexamethasone
(VD) for Patients with Multiple Myeloma Who
Have Completed a Dexamethasone-Based
Induction Regimen
CTSU E1A06
Consent
HIPAA
Protocol
An Intergroup
Phase III Randomized Controlled Trial Comparing
Melphalan, Prednisone and Thalidomide Versus
Melphalan, Prednisone and Lenalidomide in Newly
Diagnosed Myeloma Patients Who Are Not
Candidates for High-Dose Therapy
SWOG S0115
Consent
HIPAA Fast
Facts
Protocol
Phase II Trial
Evaluating Modified High Dose Melphalan and Autologous Peripheral Blood Stem Cell
Supported Transplantation for High Risk Patients with Multiple Myeloma and/or Light Chain
Amyloidosis
SWOG S0120
Consent HIPAA
Fast Facts
Protocol
A Prospective
Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and
Plasma Proliferative Disorders
SWOG S0309
(No Consent)
HIPAA
Protocol
Myeloma Specimen
Repository Protocol, Ancillary
SWOG S0434
Consent HIPAA
Protocol
(Temporary closure 7/1/08)
A Phase II Trial of BAY 43-9006 (Sorafenib)
in Patients with Relapsing or Resistant Multiple Myeloma Previously Treated with
Bortezomib
SWOG S0777
Consent
